BriaCell Therapeutics (BCTX) Highlights Additional Phase 3 Clinical Sites

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) is pleased to announce the addition of two key large cancer centers to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as NCT06072612): Los Angeles Cancer Network and Smilow Cancer Hospital at New Haven. Each has 15 satellite locations. BriaCell anticipates completing patient enrollment in late 2025 or early 2026 and may report top line data as early as H1-2026.

BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT™, plus immune check point inhibitor (CPI) versus physician’s choice in advanced metastatic breast cancer (Bria-ABC).

“Clinical investigator interest in our Phase 3 study has exceeded our expectations which has significantly expanded patient access to our treatment,” stated Giuseppe Del Priore, MD, MPH, BriaCell’s Chief Medical Officer. “This strong engagement reflects both the urgent unmet need in metastatic breast cancer and the dedication of our clinical partners.”

Interim data will be analyzed once 144 patient events (deaths) occur, comparing the overall survival (OS) in patients treated with the Bria-IMT combination regimen versus those treated with physician’s choice as the primary endpoint. Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria-IMT in MBC patients. BriaCell recently (ASCO 2025) announced positive Phase 2 survival data in a similar MBC patient population treated with the same Bria-IMT combination regimen. The Bria-IMT combination regimen has received FDA Fast Track designation.

For additional information on BriaCell’s pivotal Phase 3 study of Bria-IMT and an immune check point inhibitor in metastatic breast cancer, please visit ClinicalTrials.gov NCT06072612.

You May Also Be Interested In

• Novartis drug shows efficacy in chronic urticaria trial
• Deutsche Aircraft partners with Hexcel for D328eco composite materials
• Wolfe Research Starts SpaceX (SPCX) at Outperform